The quarter showcased the company's ability to drive topline expansion whilst grappling with profitability headwinds. Net sales climbed to ₹485.20 crores in Q4 FY26, marking sequential growth of 7.59% from ₹450.99 crores in Q3 FY26 and a substantial 21.82% year-on-year increase from ₹398.29 crores. However, this revenue momentum failed to translate into proportionate bottom-line growth, as operating margins contracted sharply to 6.72% from 8.28% in the previous quarter and 6.84% in the year-ago period.
For the full fiscal year FY25, Jubilant Agri reported consolidated net sales of ₹1,561.00 crores, representing robust growth of 24.60% from ₹1,253.00 crores in FY24. Annual profit after tax surged to ₹88.00 crores from ₹30.00 crores, though this comparison benefits from a low base effect. The company's nine-month performance for FY26 showed sales of ₹1,449.14 crores, up 20.47%, with PAT of ₹86.31 crores, reflecting 38.65% growth.
| Quarter | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 | Dec'24 | Sep'24 |
|---|---|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 485.20 | 450.99 | 512.95 | 441.95 | 398.29 | 397.52 | 407.08 |
| QoQ Growth | +7.59% | -12.08% | +16.07% | +10.96% | +0.19% | -2.35% | — |
| YoY Growth | +21.82% | +13.45% | +26.01% | — | — | — | — |
| Net Profit (₹ Cr) | 19.93 | 21.52 | 42.28 | 44.13 | 16.01 | 21.34 | 24.69 |
| QoQ Growth | -7.39% | -49.10% | -4.19% | +175.64% | -24.98% | -13.57% | — |
| YoY Growth | +24.48% | +0.84% | +71.24% | — | — | — | — |
| Operating Margin | 6.72% | 8.28% | 12.49% | 14.37% | 6.84% | 8.65% | 10.33% |
| PAT Margin | 4.12% | 4.79% | 8.26% | 10.00% | 4.03% | 5.39% | 6.15% |
Financial Performance: Growth Amid Margin Pressure
The quarter's financial performance reveals a company navigating conflicting dynamics. Revenue growth of 21.82% year-on-year demonstrates strong demand momentum, yet profitability metrics paint a more concerning picture. Operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) declined to ₹32.53 crores from ₹37.23 crores sequentially and ₹27.16 crores in the year-ago quarter. This translated to operating margins compressing by 156 basis points quarter-on-quarter to 6.72% and declining 12 basis points year-on-year.
The margin erosion appears driven by rising employee costs, which increased to ₹53.59 crores in Q4 FY26 from ₹52.61 crores in Q3 FY26 and ₹46.75 crores in Q4 FY25, representing 11.04% of sales versus 9.34% in the previous quarter. Total expenditure management remained challenged as the company scaled operations. Profit before tax stood at ₹26.59 crores, down 8.29% sequentially but up 25.25% year-on-year, with tax incidence at 25.05%.
PAT margins contracted to 4.12% in Q4 FY26 from 4.79% in the previous quarter and 4.03% in the year-ago period. Whilst the year-on-year comparison shows marginal improvement, the sequential deterioration and the sharp variance from mid-year peaks (8.26% in Q2 FY26 and 10.00% in Q1 FY26) highlight the profitability challenges. Interest costs declined to ₹1.56 crores from ₹1.97 crores sequentially, reflecting improved debt management, but this benefit was insufficient to offset operational pressures.
Operational Excellence: Strong Returns Despite Margin Volatility
Jubilant Agri's operational performance showcases commendable capital efficiency despite the margin compression witnessed in recent quarters. The company's return on equity (ROE) stands at an impressive 29.83% for the latest quarter, significantly outpacing the speciality chemicals sector average. This metric, which measures how effectively the company generates profits from shareholder capital, demonstrates management's ability to deploy resources productively. The average ROE over recent periods of 25.01% further reinforces this strength, positioning Jubilant Agri amongst the more efficient operators in its peer group.
Return on capital employed (ROCE) tells a similar story, with the latest figure at 38.77% and an average of 28.42% over time. These elevated returns indicate that the company generates substantial operating profits relative to the capital invested in the business. The ability to maintain such high returns whilst simultaneously expanding the topline at over 20% annually reflects operational leverage and effective asset utilisation. Notably, the company's sales to capital employed ratio of 3.45 times demonstrates efficient capital turnover.
Balance sheet quality remains robust, with debt levels well under control. The debt-to-EBITDA ratio stands at a comfortable 0.79 times, whilst net debt to equity averages just 0.07, indicating minimal leverage. Long-term debt declined to ₹8.50 crores in FY25 from ₹24.59 crores in FY24, demonstrating active deleveraging. The company's EBIT-to-interest coverage averaged 18.43 times, providing substantial cushion for debt servicing. Shareholder funds strengthened to ₹325.51 crores from ₹235.27 crores, driven by retained earnings accumulation.
⚠️ Key Monitoring Point: Margin Trajectory
Whilst Jubilant Agri demonstrates strong capital efficiency with ROE above 29%, the sharp margin compression from peak levels demands attention. Operating margins peaked at 14.37% in Q1 FY26 but have since declined to 6.72% in Q4 FY26. The company's ability to stabilise and improve margins will be critical for sustaining its premium valuation and growth trajectory. Rising employee costs and operational expenditure need careful management to protect profitability.
Industry Context: Outperforming a Challenging Sector
The speciality chemicals sector has faced headwinds over the past year, with the industry delivering negative returns of -4.40% over 12 months. Against this backdrop, Jubilant Agri's stock performance of +17.56% over the same period represents significant outperformance of 21.96 percentage points versus its sector. This relative strength reflects investor recognition of the company's growth momentum and operational improvements, even as broader sector sentiment remained subdued due to pricing pressures, inventory corrections, and demand uncertainties in key export markets.
The company's five-year sales growth of 23.10% CAGR and EBIT growth of 41.53% CAGR position it favourably within the speciality chemicals universe. Whilst competitors grappled with demand normalisation and margin pressures post-pandemic, Jubilant Agri sustained its growth trajectory through FY26. The company's focus on agri-inputs and consumer products provides some insulation from purely chemical commodity cycles, offering more stable demand patterns linked to agricultural activity and rural consumption.
However, the margin compression witnessed in recent quarters mirrors broader industry trends of input cost volatility and competitive intensity. Raw material price fluctuations, energy costs, and logistics expenses have pressured realisations across the sector. The company's ability to pass through costs whilst maintaining volume growth will determine whether the current margin levels represent a temporary trough or a structural reset to lower profitability.
Peer Comparison: Premium Valuation for Superior Returns
Jubilant Agri commands a premium valuation relative to its speciality chemicals peers, justified by its superior return profile. With a price-to-earnings ratio of 21.32x, the stock trades at a discount to sector heavyweight NOCIL (47.41x) and Tatva Chintan (63.49x), but at a premium to Rossari Biotech (19.85x) and Styrenix Performance (21.09x). More significantly, the company's price-to-book value of 6.70x substantially exceeds the peer average of approximately 2.80x, reflecting investor willingness to pay for quality and growth.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Jubilant Agri | 21.32 | 6.70 | 25.01% | 0.07 | — |
| Styrenix Performance | 21.09 | 2.92 | 16.52% | 0.12 | 2.38% |
| Foseco India | 38.70 | 3.62 | 17.21% | -0.29 | — |
| Rossari Biotech | 19.85 | 2.22 | 11.80% | 0.23 | — |
| NOCIL | 47.41 | 1.59 | 7.76% | -0.19 | 1.19% |
| Tatva Chintan | 63.49 | 3.42 | 8.01% | 0.14 | 0.09% |
The valuation premium becomes justifiable when examining return metrics. Jubilant Agri's ROE of 25.01% significantly outpaces Styrenix Performance (16.52%), Foseco India (17.21%), and substantially exceeds NOCIL (7.76%) and Tatva Chintan (8.01%). Only Rossari Biotech approaches double-digit returns at 11.80%, but still trails Jubilant Agri by a wide margin. This superior capital efficiency explains why investors accord the company a higher price-to-book multiple.
From a leverage perspective, Jubilant Agri maintains one of the cleanest balance sheets in the peer group with a debt-to-equity ratio of just 0.07, comparable to Styrenix Performance (0.12) and better than Rossari Biotech (0.23) and Tatva Chintan (0.14). The combination of high returns and low leverage creates a compelling risk-reward profile that supports premium valuation. The company's market capitalisation of ₹2,929.00 crores positions it as the fourth largest in this peer set, offering reasonable liquidity for institutional investors.
Valuation Analysis: Expensive but Justified by Quality
At the current price of ₹1,841.55, Jubilant Agri trades at valuation multiples that classify it as "expensive" based on historical standards and peer comparisons. The price-to-earnings ratio of 21.32x sits above the long-term average for speciality chemicals companies, whilst the price-to-book value of 6.70x represents a significant premium. However, this valuation must be contextualised against the company's quality metrics and growth trajectory.
The enterprise value to EBITDA multiple of 14.26x and EV/EBIT of 15.68x suggest the market is pricing in continued operational improvements and margin expansion. The PEG ratio of 0.46 indicates that relative to the company's growth rate, the valuation appears reasonable. With sales growing at 23.10% CAGR and EBIT at 41.53% CAGR over five years, the company's growth profile supports a premium to slower-growing peers.
The stock has corrected 39.26% from its 52-week high of ₹3,032.00, currently trading 27.15% above its 52-week low of ₹1,448.30. This correction from peak valuations has improved the risk-reward proposition, though the stock remains elevated on absolute metrics. Book value per share of ₹216.04 implies the current price represents a 6.70x premium to tangible equity, which is sustainable only if the company maintains its superior return profile.
Shareholding Pattern: Stable Promoter Base with Minimal Institutional Interest
The shareholding structure of Jubilant Agri reflects a tightly held promoter base with limited institutional participation. Promoter holdings stood at 74.36% as of March 2026, marginally declining from 74.37% in December 2025 and 74.78% in September 2025. The 42 basis point reduction over two quarters represents minor stake adjustments rather than any significant divestment. Key promoter entities include Hsb Trustee Company Pvt Ltd (35.10%) and Spb Trustee Company Pvt Ltd (34.54%), ensuring management control remains firmly entrenched.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter | 74.36% | 74.37% | 74.78% | 74.78% | -0.01% |
| FII | 0.27% | 0.24% | 0.25% | 0.15% | +0.03% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.02% | 0.02% | 0.02% | 0.02% | 0.00% |
| Other DII | 0.12% | 0.13% | 0.10% | 0.06% | -0.01% |
| Non-Institutional | 25.24% | 25.24% | 24.85% | 24.99% | 0.00% |
Institutional holdings remain negligible, with FIIs holding just 0.27%, insurance companies at 0.02%, and other domestic institutional investors at 0.12%. Notably, mutual funds have zero exposure to the stock, indicating limited interest from mainstream institutional investors. The total institutional holding of 0.41% highlights the stock's positioning as a promoter-driven, retail-focused investment rather than an institutional favourite. This ownership structure can lead to lower liquidity and higher volatility, as evidenced by the stock's beta of 1.46.
Non-institutional investors, primarily comprising retail shareholders and high-net-worth individuals, hold 25.24% of equity. The stable shareholding pattern with minimal quarter-on-quarter changes suggests a patient investor base aligned with the company's long-term growth story. The absence of promoter pledging (0.0%) provides comfort regarding financial stability and eliminates concerns about forced selling in adverse market conditions.
Stock Performance: Volatile but Outperforming Benchmarks
Jubilant Agri's stock performance over the past year demonstrates significant volatility characteristic of small-cap speciality chemical companies, yet delivers positive absolute returns that substantially outperform broader market indices. Over one year, the stock generated returns of 17.56% against the Sensex decline of -6.97%, creating alpha of 24.53 percentage points. This outperformance reflects investor confidence in the company's growth trajectory despite sector headwinds.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | -0.14% | -0.19% | +0.05% |
| 1 Week | 6.69% | 0.73% | +5.96% |
| 1 Month | 4.62% | -1.86% | +6.48% |
| 3 Months | 0.88% | -6.67% | +7.55% |
| 6 Months | -21.73% | -11.49% | -10.24% |
| YTD | -18.53% | -10.97% | -7.56% |
| 1 Year | 17.56% | -6.97% | +24.53% |
However, shorter-term performance reveals considerable volatility. The stock declined 21.73% over six months, underperforming the Sensex decline of -11.49% by 10.24 percentage points. Year-to-date returns stand at -18.53%, worse than the Sensex's -10.97% decline. This recent weakness reflects concerns about margin compression and the correction from elevated valuations reached in late 2025. The stock touched a 52-week high of ₹3,032.00 before retreating to current levels around ₹1,841.55.
Near-term momentum appears to be stabilising, with the stock gaining 6.69% over one week and 4.62% over one month, outperforming the Sensex in both periods. The stock trades below all key moving averages—5-day (₹1,796.33), 20-day (₹1,765.57), 50-day (₹1,725.62), 100-day (₹1,887.63), and 200-day (₹2,178.47)—indicating technical weakness. The risk-adjusted return of 0.29 with volatility of 59.59% classifies the stock as "high risk, high return," reflecting its small-cap nature and sector dynamics.
Investment Thesis: Quality Company at Inflection Point
Jubilant Agri presents a nuanced investment case combining strong fundamental quality with near-term execution concerns. The company's proprietary investment score of 61 out of 100 translates to a "HOLD" rating, upgraded from "SELL" in August 2025. This improvement reflects recognition of the company's robust long-term growth trajectory and improving financial health, though cautions remain about margin sustainability and expensive valuation.
The quality assessment grades the company as "average," reflecting long-term financial performance that meets but does not exceed expectations. Five-year sales growth of 23.10% and EBIT growth of 41.53% demonstrate consistent expansion, whilst average ROCE of 28.42% and ROE of 25.01% showcase efficient capital deployment. The company's debt-to-EBITDA ratio of 0.79 and net debt-to-equity of 0.07 indicate conservative leverage, with no promoter pledging providing additional comfort.
The financial trend classification as "flat" for Q4 FY26 captures the mixed quarterly performance—strong topline growth offset by margin compression. Whilst nine-month metrics show healthy expansion (sales up 20.47%, PAT up 38.65%), the quarterly profit before tax excluding other income declined 37.50% versus the previous four-quarter average, triggering the flat classification. Technical indicators turned "mildly bullish" on May 26, 2026, suggesting potential near-term momentum, though the stock remains below all major moving averages.
Key Strengths & Risk Factors
✓ Key Strengths
- Superior Capital Efficiency: ROE of 29.83% and ROCE of 38.77% significantly outpace industry averages, demonstrating exceptional management quality and competitive advantages
- Robust Revenue Growth: Five-year sales CAGR of 23.10% and recent quarterly growth of 21.82% YoY showcase strong demand and market share gains
- Pristine Balance Sheet: Debt-to-EBITDA of 0.79x and net debt-to-equity of 0.07 provide financial flexibility and eliminate refinancing risks
- Strong Interest Coverage: EBIT-to-interest ratio of 18.43x offers substantial cushion for debt servicing and supports growth investments
- Zero Promoter Pledging: Absence of pledged shares eliminates concerns about forced selling and demonstrates promoter confidence
- Market Outperformance: One-year returns of 17.56% versus Sensex decline of -6.97% reflect investor confidence in the growth story
- Sector Leadership: 21.96 percentage point outperformance versus speciality chemicals sector validates competitive positioning
⚠ Key Concerns
- Severe Margin Compression: Operating margins declined from 14.37% peak in Q1 FY26 to 6.72% in Q4 FY26, raising sustainability concerns
- Sequential Profit Decline: Net profit fell 7.39% QoQ despite 7.59% revenue growth, indicating operating leverage deterioration
- Expensive Valuation: P/BV of 6.70x and classification as "expensive" limit upside potential and increase downside risk
- Minimal Institutional Holding: Total institutional ownership of just 0.41% suggests limited institutional conviction and liquidity constraints
- High Volatility: Beta of 1.46 and volatility of 59.59% make the stock unsuitable for risk-averse investors
- Technical Weakness: Trading below all major moving averages indicates lack of sustained buying interest
- Rising Employee Costs: Employee expenses as percentage of sales increased to 11.04% from 9.34%, pressuring profitability
Outlook: What to Watch
Positive Catalysts
- Margin Recovery: Stabilisation and improvement in operating margins back towards 10-12% range would validate premium valuation
- Sustained Revenue Growth: Continuation of 20%+ topline expansion whilst improving profitability would drive earnings acceleration
- Institutional Interest: Entry of mutual funds or increased FII participation could provide valuation support and liquidity
- Operating Leverage: Improved cost management and operating leverage as scale benefits materialise
Red Flags to Monitor
- Further Margin Erosion: Operating margins falling below 6% would signal structural profitability challenges
- Revenue Growth Deceleration: Topline growth slowing below 15% without margin improvement would pressure earnings
- Working Capital Deterioration: Increasing receivables or inventory days indicating demand softness or collection issues
- Valuation Compression: Stock breaking below ₹1,450 (52-week low) would indicate loss of investor confidence
The Verdict: Quality Company, Await Better Entry
Score: 61/100
For Fresh Investors: Avoid initiating positions at current levels. Whilst the company demonstrates strong fundamentals with superior ROE of 29.83% and robust revenue growth, the expensive valuation (P/BV of 6.70x) and concerning margin compression from 14.37% to 6.72% create unfavourable risk-reward. Wait for either margin stabilisation evidence or a correction towards ₹1,600-1,650 levels before considering entry.
For Existing Holders: Continue holding with vigilant monitoring of quarterly margin trends. The company's pristine balance sheet, zero promoter pledging, and superior capital efficiency justify patience. However, set a mental stop-loss around ₹1,450 (52-week low). If margins fail to recover towards 9-10% by Q2 FY27, consider reducing exposure.
Fair Value Estimate: ₹1,950-2,050 (6-11% upside), contingent on margin recovery to 9-10% range and sustained 20%+ revenue growth. Current price of ₹1,841.55 offers limited upside given execution risks.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results. Investments in equity markets are subject to market risks, and investors may lose part or all of their invested capital.
